The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wieder, K. J.
Right arrow Articles by Kupiec-Weglinski, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wieder, K. J.
Right arrow Articles by Kupiec-Weglinski, J. W.

The Journal of Immunology, Vol 151, Issue 2 1158-1166, Copyright © 1993 by American Association of Immunologists


ARTICLES

Rapamycin treatment depresses intragraft expression of KC/MIP-2, granzyme B, and IFN-gamma in rat recipients of cardiac allografts

KJ Wieder, WW Hancock, G Schmidbauer, CL Corpier, I Wieder, L Kobzik, TB Strom and JW Kupiec-Weglinski
Harvard Medical School, Department of Medicine, Beth Israel Hospital, Boston, MA 02215.

Rapamycin (RPM) treatment prevents accelerated rejection of cardiac allografts in sensitized rats. The prominent feature of this brisk 24-h rejection, which includes a panoply of both cellular and humoral host immune responses, is a massive infiltration of rejecting grafts with neutrophils. In this study we tested the hypothesis that RPM-mediated therapeutic effects on accelerated rejection may be linked to decreased expression of protein encoded by gro/melanoma-growth stimulatory activity gene (KC) and macrophage inflammatory protein-2 (MIP-2) genes, the operational rat homologues of the human intercrine-alpha cytokines with proinflammatory IL-8-like neutrophil activation/chemotactic properties. The induction of these genes was then correlated with mRNA profiles encoding for Th1-selective IFN-gamma and CTL-specific granzyme B proteins. Northern blot analysis of RNA from cardiac allografts of sensitized untreated recipients, revealed maximal levels of KC and MIP- 2 mRNA at 3 to 6 h after transplantation. In contrast, IFN-gamma mRNA, which was at most very weakly expressed at 3 h, peaked between 6 to 12 h. As with IFN-gamma, granzyme B transcripts were undetectable at 3 h, but peaked around the time of actual graft rejection at 24 h. RPM therapy abrogated accelerated rejection and prolonged cardiac allograft survival to ca. 46 days. This effect was associated with markedly reduced expression of KC and MIP-2 mRNA in the first 24 h as well as at 7 and 34 days after transplantation. Moreover, RPM completely blocked intragraft appearance of granzyme B and IFN-gamma mRNA in long term cardiac allografts. Immunohistologic analysis has revealed that accelerated rejection was associated with extensive neutrophil infiltration, which peaked at 18 to 24 h. At this time, leukocytes and endothelium were intensely stained for IL-8 and IFN-gamma antibodies. In contrast, the allografts from RPM-treated hosts showed essentially no neutrophil infiltration and minor, focal staining for IL-8 and IFN- gamma. This study demonstrates an association between the early expression of genes for proinflammatory IL-8-dependent neutrophil chemotactic activity, and later expression of genes associated with activation/effector activity of CTL and NK cells. It also documents a novel effect of RPM in vivo, which results in the suppression of intragraft IL-8-like and CTL-dependent mRNA/protein production and diminished neutrophil infiltration; these may contribute to the striking efficacy of RPM therapy in sensitized graft recipients.


This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
T. B. Strom
2006 Homer W. Smith Lecture: Taming T Cells
J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2824 - 2832.
[Full Text] [PDF]


Home page
JEMHome page
W. W. Hancock, W. Gao, V. Csizmadia, K. L. Faia, N. Shemmeri, and A. D. Luster
Donor-Derived Ip-10 Initiates Development of Acute Allograft Rejection
J. Exp. Med., April 16, 2001; 193(8): 975 - 980.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Watarai, S. Koga, D. R. Paolone, T. M. Engeman, C. Tannenbaum, T. A. Hamilton, and R. L. Fairchild
Intraallograft Chemokine RNA and Protein During Rejection of MHC-Matched/Multiple Minor Histocompatibility-Disparate Skin Grafts
J. Immunol., June 1, 2000; 164(11): 6027 - 6033.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. R. Blazar, P. A. Taylor, A. Panoskaltsis-Mortari, and D. A. Vallera
Rapamycin Inhibits the Generation of Graft-Versus-Host Disease- and Graft-Versus-Leukemia-Causing T Cells by Interfering with the Production of Th1 or Th1 Cytotoxic Cytokines
J. Immunol., June 1, 1998; 160(11): 5355 - 5365.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
J. Dunlevy and J. Couchman
Interleukin-8 induces motile behavior and loss of focal adhesions in primary fibroblasts
J. Cell Sci., January 1, 1995; 108(1): 311 - 321.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.